When Patricia Brown-Cook checked into a California clinic for an infusion of Merck’s blockbuster cancer drug Keytruda, one line dominated her bill: a charge just over $162,000 for a single 400-milligram dose.
While Brown-Cook owed only about $2,000 out of pocket, the staggering six-figure charge to her insurance company illustrates how quickly cutting-edge medical treatments can balloon in the U.S. healthcare system. USA TODAY Health Reporter Ken Alltucker investigated the issue as part of a year-long effort with the International Consortium of Investigative Journalists, looking into rising healthcare costs worldwide.
What Is Keytruda and How Much Does It Cost?
Keytruda is an immunotherapy drug approved for several cancers, including melanoma and advanced breast cancer. It uses the body’s own immune system to fight cancer and has become the leading edge of that approach.
The list price starts at just over $12,000 for a 200-milligram dose. A 400-milligram dose is also available. The 200-milligram dose is taken every three weeks; the 400-milligram dose every six weeks. What a patient actually pays depends heavily on their insurance plan — and crucially, where they receive the drug, since prices can escalate as a medication moves through the U.S. supply chain.
Why Does It Cost So Much More in the U.S.?
The U.S. price for Keytruda is generally the most expensive in the world. Western European nations with government-run healthcare systems negotiate and set prices directly. In the U.S., drug companies are largely free to charge what the market will bear.
When a company like Merck develops a new treatment, it is allowed to set its own price once the drug reaches the market. Patents — typically lasting about 20 years from the application date — prevent competitors from making a generic version in the meantime.
For Keytruda, the first patents expire in 2028. After that, biosimilar or generic competitors could enter the market and drive prices down, as typically happens with other drugs.
Questions About Dosage
A researcher in Israel has argued that a lower dose of Keytruda may be equally effective, and some hospitals in Asia have experimented with reduced dosing. Merck, however, conducted its clinical trials at the FDA-approved 200-milligram and 400-milligram levels and maintains that is what the science supports.
Note: This reporting does not accuse Merck of any illegal activity. The practices described are standard in the drug industry. The focus is on why medical costs remain persistently high in the United States.
What Could Change?
There is growing political pressure to rein in healthcare costs. Key developments to watch:
- ACA subsidies: Subsidies that made Affordable Care Act health plans less expensive for millions of Americans ended at the start of 2026. Democrats are pushing to restore them.
- Medicaid cuts: The Republican budget bill includes forthcoming Medicaid reductions, which will affect millions who gained coverage under the ACA expansion.
- Medicare drug negotiations: Medicare — the program covering Americans 65 and older — has begun negotiating drug prices for its population, a significant shift in what has historically been a free-market system.
- Price transparency: Advocates argue that greater transparency would empower both patients and employers (who provide insurance to most working-age Americans) to negotiate better rates.
Healthcare now consumes nearly one in every $5 spent in the United States — and until structural reforms take hold, that cost will continue to flow through to premiums, copays, and taxes.
The Bottom Line
Innovation like Keytruda can be life-changing. But the U.S. drug pricing pipeline means that by the time a treatment reaches a patient’s infusion chair, costs have often escalated far beyond the original list price. For retirees and others on fixed incomes relying on Medicare or private insurance, those costs rarely stay invisible for long.
Add a Comment